The specialty pharmacy space has been in somewhat of a rut when it comes to M&A–but that won’t last, Moody’s says.
Look for specialty players to “return to more active M&A” going forward, SVP Michael Levesque wrote in the company’s recently released Healthcare Quarterly report. And look for them to snatch up more innovative drugs than they have in the past.
The reason? Politicians, the public and the media alike have been closely watching the sector’s M&A strategy over the past several months. You know the one, made famous by Valeant and Martin Shkreli’s Turing: Buy a product and immediately turn around and send its list price soaring.
It’s landed several others besides Valeant and Turing in trouble–see: Horizon, Mallinckrodt–and now specialty drugmakers, who typically made “limited investments in internal R&D,” are ready to change their ways, Levesque says.
Dublin drugmakers Jazz and Horizon have already spearheaded the movement, he points out, with their respective $1.5 billion pickup of Celator and $800 million acquisition of Raptor. “We anticipate more deals of this variety,” he wrote.
One specialty player who won’t be getting back in on the M&A action? Valeant. The Canadian drugmaker has pledged to stay away from the dealmaking table in an effort to get its debt–piled up sky-high after years of rampant dealmaking under former CEO J. Michael Pearson–under control. In the meantime, though, it hasn’t steered completely clear of price hikes: Earlier this year, the company announced it would be jacking some list prices up by between 2% and 9%.
By Carly Helfand
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
